Suicidal Events in the Treatment for Adolescents With Depression Study (TADS)

Benedetto Vitiello, MD; Susan G. Silva, PhD; Paul Rohde, PhD; Christopher J. Kratochvil, MD; Betsy D. Kennard, PsyD;
Mark A. Reinecke, PhD; Taryn L. Mayes, MS; Kelly Posner, PhD; Diane E. May, MSN; and John S. March, MD, MPH

Objective: The Treatment for Adolescents with Depression Study (TADS) database was analyzed to determine whether suicidal events (attempts and ideation) occurred early in treatment, could be predicted by severity of depression or other clinical characteristics, and were preceded by clinical deterioration or symptoms of increased irritability, akathisia, sleep disruption, or mania.

Method: TADS was a 36-week randomized, controlled clinical trial of pharmacologic and psychotherapeutic treatments involving 439 youths with major depressive disorder (DSM-IV criteria). Suicidal events were defined according to the Columbia Classification Algorithm of Suicidal Assessment. Patients were randomly assigned into the study between spring 2000 and summer 2003.

Results: Forty-four patients (10.0%) had at least 1 suicidal event (no suicide occurred). Events occurred 0.4 to 31.1 weeks (mean \pm SD = 11.9 \pm 8.2) after starting TADS treatment, with no difference in event timing for patients receiving medication versus those not receiving medication. Severity of self-rated pretreatment suicidal ideation (Suicidal Ideation Questionnaire adapted for adolescents score \geq 31) and depressive symptoms (Reynolds Adolescent Depression Scale score \geq 91) predicted occurrence of suicidal events during treatment (P < .05). Patients with suicidal events were on average still moderately ill prior to the event (mean ± SD Clinical Global Impressions-Severity of Illness scale score = 4.0 ± 1.3) and only minimally improved (mean ± SD Clinical Global Impressions-Improvement scale score = 3.2 ± 1.1). Events were not preceded by increased irritability, akathisia, sleep disturbance, or manic signs. Specific interpersonal stressors were identified in 73% of cases (N = 44). Of the events, 55% (N = 24) resulted in overnight hospitalization.

Conclusions: Most suicidal events occurred in the context of persistent depression and insufficient improvement without evidence of medication-induced behavioral activation as a precursor. Severity of self-rated suicidal ideation and depressive symptoms predicted emergence of suicidality during treatment. Risk for suicidal events did not decrease after the first month of treatment, suggesting the need for careful clinical monitoring for several months after starting treatment. J Clin Psychiatry 2009;70(5):741–747

© Copyright 2009 Physicians Postgraduate Press, Inc.

741

Received August 8, 2008; accepted November 24, 2008. From the National Institute of Mental Health, Bethesda, Maryland (Dr Vitiello); Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina (Drs Silva and March); University of Oregon, Eugene (Dr Rohde); University of Nebraska, Omaha (Dr Kratochvil and Ms May); University of Texas Southwestern Medical Center, Dallas (Dr Kennard and Ms Mayes); Northwestern University, Chicago, Illinois (Dr Reinecke); and Columbia University, New York, New York (Dr Posner).

The Treatment for Adolescents with Depression Study was supported by contract N01 MH80008 from the National Institute of Mental Health, Bethesda, MD, to Duke University Medical Center, Durham, NC.

The opinions and assertions contained in this publication are the private views of the authors and are not to be construed as official or as reflecting the views of the National Institute of Mental Health, the National Institutes of Health, or the Department of Health and Human Services.

Financial disclosure appears at the end of this article. Corresponding author and reprints: Benedetto Vitiello, MD, NIMH, Room 7147, 6001 Executive Blvd, Bethesda, MD 20892-9633 (e-mail: bvitiell@mail.nih.gov).

The presence of suicidal ideation or behavior is among the diagnostic criteria for major depressive disorder, but it is neither necessary nor sufficient for the diagnosis.¹ Nonetheless, suicidal behavior is strongly linked to depression in both adults and adolescents.² Besides depression, history of previous suicide attempts, presence of psychosis, alcohol or substance abuse, sleep disturbance, and comorbidity of depression with anxiety or disruptive behavior are psychiatric risk factors for suicidal behavior.²⁻⁴ In addition, demographic characteristics, such as gender and race/ethnicity, and contextual factors, such as family conflict, dysfunctional attitudes, and other environmental stressors, contribute to the risk.²

Perhaps not surprisingly given the multifactorial origin of these phenomena, the relationship between suicidal behavior and depression remains poorly understood. No clinically useful predictors of developing suicidality during treatment are known for depressed adolescents who have no specific history of suicidal behavior. Moreover, while suicidal tendencies can stem from feelings of hopelessness, worthlessness, or guilt, which are core symptoms of depression, it has been clinically observed that suicidality can also emerge when depression seems to lift and patients improve.⁵ The finding of an association between antidepressant treatment and an increased rate of suicidal ideation and behavior in pediatric controlled clinical trials of antidepressants has added a further layer of complexity to the relationship among depression, its treatment, and suicidality.^{6,7}

The mechanism through which antidepressant medication might increase suicidal ideation and behavior is unknown. It has been proposed that antidepressants may induce behavioral activation, including anxiety, irritability, agitation, and insomnia, which would facilitate suicidal ideation and behavior.⁸ If this were the case, one would expect that the incidence of suicidal events would be highest at the beginning of antidepressant treatment. Analyses of community clinical practice databases have indeed indicated that the rate of suicidal behavior is highest in the first month of treatment and especially during the first 9 days.⁹ In other analyses of health claim data, the rate was actually the highest in the month prior to starting antidepressant medication with a gradual decline during treatment.^{10,11}

This pattern likely reflects the fact that, in usual practice, antidepressants are often started at a time of increasing depression and acute distress. If treatment is started during a crisis, it is not surprising that the suicide risk is highest before treatment and tends to decrease in time as the crisis resolves. In any case, current practice guidelines recommend that clinicians and family members closely monitor adolescents during the first few weeks of antidepressant treatment.¹²

The Treatment for Adolescents with Depression Study (TADS) was a 36-week controlled clinical trial that included outpatients with moderate to severe major depressive disorder, but excluded youths considered at especially high risk for suicide due to recent history of suicidal behavior or prominent suicidal ideation, or with comorbid substance abuse or severe conduct disorder. The main outcomes of TADS have been reported, ^{13,14} including suicidal events by treatment and a detailed analysis of the first 12 weeks of safety data.¹⁵ During the 36-week TADS treatment, 9.8% of the patients randomly assigned to active treatment presented with a suicidal event. The rate was higher (P < .05) in the fluoxetine (14.7%) than in the psychotherapy group (6.3%), which was not different from the combined treatment group (8.4%), while the combined treatment and fluoxetine groups did not significantly differ from each other.14

For this report, we analyzed the TADS database to address the following 5 questions. First, was the rate of suicidal events highest in the first few weeks of treatment? Based on previous population epidemiologic data, it was expected that peak incidence would occur within the first 3 to 4 weeks of treatment. Second, could pretreatment clinical characteristics predict emergence of a suicidal event during treatment? Specifically, it was hypothesized that severity of depression, comorbid anxiety, and suicidal ideation at treatment entry would be associated with greater risk for suicidal events during treatment. Third, what was the clinical status of the youths with suicidal behavior proximally to the event? On the basis of the known link between depression and suicidal behavior, it was predicted that most suicidal patients would still be depressed and not improved.

Fourth, did the youths with a suicidal event present signs of behavioral activation prior to the event? We hypothesized that a substantial number of suicidal youths would present symptoms of behavioral activation in the 2 weeks prior to the suicidal event and that this association with behavioral activation would be specifically present if the patient was receiving antidepressant medication. Fifth, what were the most common consequences of a suicidal event with respect to patient disposition and treatment? It was expected that most events would lead to emergency room visits or overnight hospitalization.

METHOD

TADS

TADS was a publicly funded, randomized clinical trial to evaluate the acute (12 weeks) and long-term (36 weeks) effectiveness of fluoxetine, cognitive-behavioral therapy (CBT), and their combination in the treatment of adolescents with major depressive disorder.^{13,14,16} A placebo condition was included as a control for the first 12 weeks, after which all treatments were unblinded. Patients who were deemed responders or partial responders, as documented by a score of minimally improved or better on the Clinical Global Impressions-Improvement scale (CGI-I),¹⁷ continued with their assigned treatment up to the end of the 36-week trial. Nonresponders were discontinued from study treatment and managed as clinically indicated while still participating in the remaining assessments through week 36. Patients were randomly assigned into the study between spring 2000 and summer 2003.

The TADS sample consisted of 439 adolescents aged 12-17 years (mean \pm SD = 14.6 ± 1.5 years; 206 aged 12-14 years and 233 aged 15-17 years), of whom 54% were female and 74% were white, who met criteria for major depressive disorder according to DSM-IV criteria. For 86% of the participants, it was the first episode of major depressive disorder, and the median duration was 40 weeks.¹³ Most patients had a comorbid condition, most frequently an anxiety disorder (27%), disruptive behavior disorder (23%), or attention-deficit/hyperactivity disorder (ADHD) (14%). Exclusion criteria included current substance abuse or dependence, severe conduct disorder, thought disorders, bipolar disorder, suicide attempt requiring medical attention within the past 6 months, clear intent or active plan to commit suicide, suicidal ideation with family disorganization, or being clinically deemed to be at "high risk" for self-injurious or aggressive acts.¹³

Randomized Treatment Assignment ^b	Ν	Suicidal Ideation (code 6), N (%)	Suicide Attempt ^c (code 1 or 2), N (%)	Total (code 1, 2, or 6), N (%
Fluoxetine and CBT	107	5 (4.7)	4 (3.7)	9 (8.4)
Fluoxetine monotherapy	109	9 (8.3)	7 (6.4)	$16(14.7)^{d}$
CBT	111	3 (2.7)	4 (3.6)	7 (6.3)
Placebo	112	6 (5.4)	6 (5.4)	12 (10.7)
Total: 4 arms	439	23 (5.2)	21 (4.8)	44 (10.0)

^aNumbers are patients with at least 1 event with code 1, 2, or 6 on the C-CASA. For patients with 2 events (N = 7), only the more severe event was included in this table.

^bTreatment at time of event was different from the randomized treatment for 3 CBT and 9 placebo patients, who had started antidepressant medication due to poor response to assigned treatment.

^cIncluded 1 episode of preparatory act toward imminent suicidal attempt (code 2). ^dHigher than in CBT (P = .04) or placebo (P = .02) when considering only the CBT and placebo patients who were not taking medication at the time of the event (Fisher exact test).

Abbreviations: CBT = cognitive-behavioral therapy, C-CASA = Columbia Classification Algorithm of Suicidal Assessment.

Assessments

Suicidal events. Adverse events were reported by patients and their parents to the treating clinicians at each study visit, which included self-report ratings of depressive symptoms, including suicidal behavior. After completion of the study, known or potential suicidal events were identified with electronic and manual searches according to the same methods used for the U.S. Food and Drug Administration meta-analyses.^{6,18} Descriptions of the events were then reviewed by independent experts at Columbia University, New York, NY, and coded according to the Columbia Classification Algorithm of Suicidal Assessment (C-CASA).¹⁸ Suicidal events consisted of discrete episodes of suicidal ideation, suicide attempts, or preparatory acts toward an imminent attempt. Harmful self-injurious acts without an expressed or inferred suicidal intent were not included.

Suicidal ideation. Suicidal ideation was systematically assessed with the Suicidal Ideation Questionnaire adapted for adolescents (SIQ-Jr),¹⁹ a 15-item patient-rated instrument administered before starting treatment and every 6 weeks afterward.^{13,14,19} A total score ≥ 31 is indicative of elevated suicidal risk ("suicidal flag"). Another index of suicidal risk was item 3 of the clinician-rated Children's Depression Rating Scale-Revised (CDRS-R),²⁰ with a score of 1 or 2 indicating no suicidal ideation, a score of 3 indicating some suicidal thinking and/or behavior, and a score of 4 or higher indicating significant concern about suicidality due to presence of persistent or recurrent ideation and/or behavior.20

In addition, the Adolescent Depression Scale (ADS), a 31-item Likert rating scale of DSM-IV depressive and related symptoms, was completed by the study clinician based on information elicited from the patient at each visit.¹⁵ On this scale, each item is rated from 0 (not present) to 3 (severe). A principal component analysis, with varimax rotation, of the ADS data from TADS identified 5 factors, including depression, mania, attention, appetite, and suicidality. The ADS depression score was correlated with the CDRS-R score at baseline (r = 0.42,

P < .0001, N = 384). Because the ADS was administered more frequently than the CDRS-R or the SIQ-Jr, it was used in these analyses to assess the clinical status of the patient immediately prior to the suicidal event.

Severity of illness, psychopathology, and improvement. Severity of illness was assessed with the CGI-Severity of Illness (CGI-S) scale,¹⁷ which was completed by the study clinician at study entry and at each treatment visit. Severity of depressive psychopathology was assessed with the clinician-rated CDRS-R, with a total score of 60 or above at study entry taken as an index of severe depression. The CDRS-R items of irritability and sleep disturbance and the Beck Hopelessness Scale (BHS)²¹ at baseline were also examined as possible predictors of suicidal events during treatment. In addition, a score above 90 on the patient self-rated Reynolds Adolescent Depression Scale (RADS)²² was considered an index of severe depression.

Presence and history of comorbid ADHD, oppositional defiant disorder (ODD), conduct disorder (CD), or substance abuse were assessed with the Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime version,²³ which was administered at baseline before starting treatment. Anxiety symptoms were assessed with the Multidimensional Anxiety Scale for Children (MASC).²⁴

Improvement compared with status at study entry was measured with the CGI-I and change in the ADS, which were completed by the clinician at each visit. Clinical status prior to the event was measured by the most proximal rating available before the event occurrence and in any case no more than 2 weeks prior to the event.

Behavioral activation. The ADS items of mania, irritability, and sleep disturbance within the 2 weeks prior to the suicidal event and their change from baseline scores were used to assess whether the event was preceded by signs suggesting behavioral activation. In addition, the adverse event database was searched for reports of akathisia, agitation, mania, sleep disturbances, irritability, or aggression during the 2 weeks prior to suicidal events.

Interpersonal stressors. The Family Assessment Measure-III General Scale overall t score and the Children's Conflict Behavior Questionnaire,^{25,26} independently completed by parent and adolescent at baseline, served as a measure of reported family conflict. The individual descriptors of the suicidal events were manually searched for any record of environmental stressors immediately prior to the event.

For each suicidal event that occurred during TADS, the reports of the clinicians describing the events were reviewed, and possible presence of interpersonal conflict immediately preceding the event was noted.

Data Analyses

Unit of analysis was the patient. Descriptive statistics were applied, and associations were

tested using χ^2 or Fisher exact test as appropriate. Statistical significance was set at a conventional P = .05 with no attempt to control for multiple testing given the exploratory intent of these analyses. For patients with more than 1 suicidal event, the suicidal event of greatest severity (eg, suicidal attempt as compared with suicidal ideation) was included in most analyses. The exception was that the first suicidal event was included in the analyses examining time to first event and clinical changes prior to first event. For each significant predictor variable identified, a receiver operator curve (ROC) was plotted in order to examine visually the relationship between sensitivity and 1-specificity as a function of the cutoff used.


RESULTS

Incidence and Timing of Suicidal Events

During the 36 weeks of TADS, 44 adolescents (10.0% of the entire sample) presented with at least 1 suicidal event, of which 23 consisted of suicidal ideation and 21 of suicide attempts (Table 1). There were no suicides. Incidence did not differ by gender (23 [9.6%] of 239 females vs 21 [10.5%] of 200 males), race/ethnicity (32 [9.9%] of 324 white vs 12 [10.4%] of 115 nonwhite), or age (22 [10.7%] of 206 patients aged 12–14 years vs 22 [9.4%] of 233 patients aged 15–17 years).

The time from entering treatment to occurrence of suicidal event ranged from 0.4 to 31.1 weeks (mean \pm SD = 11.9 \pm 8.2 weeks), with no differences among the 4 treatment arms (combined: 15.9 \pm 9.7; fluoxetine: 9.1 \pm 23.3; CBT: 11.1 \pm 8.9; placebo: 12.9 \pm 8.2; Kruskal-Wallis test: $\chi^2 = 3.5$, P = .31). Suicidal events occurred as early as a few days after entering treatment and were not less frequent in the second month of treatment as compared with the first month. In particular, none of the 21 suicide attempts occurred in the first 4 weeks (Figure 1).

Figure 1. Timing of First Suicidal Event Among Adolescents With Major Depressive Disorder (N = 44)



Abbreviations: CBT = cognitive-behavioral therapy, SSRI = selective serotonin reuptake inhibitor.

No suicidal events occurred in the last month of the 9-month treatment.

Some patients who had been randomly assigned to CBT (N = 2) or placebo (N = 9) and had a suicidal event were in fact taking selective serotonin reuptake inhibitor (SSRI) medication at the time of the event, having started antidepressant treatment because of nonresponse to the randomly assigned treatment. For these patients, time to event was recomputed by taking the time when SSRI medication was initiated as the starting point. Using this approach, for all the patients taking SSRIs at the time of the event (N = 36), the time to event was a mean \pm SD of 10.0 ± 7.7 weeks (range, 0.7-28.9), which was not statistically different from that for the patients not taking antidepressant medication at the time of the event $(N = 8; 5.8 \pm 3.2$ weeks; range, 0.4-10.4; Wilcoxon 2-sample test: z = -1.2, P = .22).

Searching for Predictors of Suicidal Events

An SIQ-Jr score of 31 or greater at baseline was significantly associated with emergence of a suicidal event during treatment. Of the 125 patients with a baseline suicide risk flag > 30, 15.2% had a suicidal event as compared with 8.3% of the 303 patients without a flag ($\chi^2 = 4.6$, P = .03, OR = 2.0, 95% CI = 1.1 to 3.8). With 31 as a cutoff, the sensitivity was 43% and specificity 72%. The ROC had an area under the curve of 63.7% and indicated that, if a cutoff score of 21 was used instead of 31, the sensitivity would be 64% and specificity 60%.

A RADS score above 90 at baseline was also associated with emergence of a suicidal event during treatment. Of the 94 patients with a baseline score above 90, 16.0% had a suicidal event as compared with 8.7% of those with a lower score ($\chi^2 = 4.2$, P = .04, OR = 2.0, 95% CI = 1.0 to 3.9). The ROC had an area under the curve of 56.0% and confirmed that a cutoff above 90 offered the best balance between sensitivity (34%) and specificity (79%).

Scale	N^{a}	At First Treatment Visit, mean ± SD	Prior to Event, mean ± SD ^b	Change, mean \pm SD ^c	Notes
Scale	1	VISIL, IIIeall \pm SD	inean ± SD	Change, mean ± 5D	Notes
CGI-S ^d	31	4.7 ± 1.3	4.0 ± 1.3	-0.8 ± 1.2	22 (74.0%) with score \geq 4 prior to event
CGI-I ^e	30	NA	3.2 ± 1.1	NA	22 (73.2%) with score \ge 3 prior to event
ADS ^f					
Depression	31	21.0 ± 7.7	13.3 ± 8.5	-8.1 ± 9.3	
Irritability	31	2.0 ± 0.9	1.7 ± 1.1	-0.3 ± 1.3	
Mania	31	2.5 ± 2.2	1.6 ± 2.2	-0.6 ± 2.3	
Insomnia	31	1.5 ± 1.1	1.1 ± 1.3	-0.4 ± 1.3	

Table 2. Clinical Status Prior to the Suicidal Event vs at First Treatment Visit Among Adolescents With Major Depressive Disorder

^aA total of 44 patients had an event. N indicates patients for whom data were available.

^bThe data most proximal to the event were included and in any case within the 2 weeks prior to the event.

^cScore prior to the event minus score at first treatment visit.

^d1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = extremely ill.

 e^{1} = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

^fDepression score included 19 items with a possible range of 0-57. The mania score included 9 items with a possible range of 0-27. Irritability and insomnia included 1 item each with a possible range of 0-3.

Abbreviations: ADS = Adolescent Depression Scale, CGI-I = Clinical Global Impressions-Improvement scale, CGI-S = Clinical Global Impressions-Severity of Illness scale, NA = not applicable.

No association was found between suicidal events and the other tested clinical characteristics, including baseline severity of depression (CDRS-R total score, CGI-S); severity of specific depressive symptoms (CDRS-R suicidal ideation, irritability, and sleep disturbance); hopelessness (BHS); anxiety symptoms (MASC); comorbidity with ADHD, ODD, or CD; family conflict; or history of substance abuse.

Clinical Status in the

745

2 Weeks Prior to the Suicidal Event

For 31 of the 44 patients with suicidal events, proximal (ie, within 2 weeks prior to the event) scores of severity of illness, improvement status (data were available for 30 patients), depression, irritability, mania, and sleep disturbances were available (Table 2). Even if depression symptoms had decreased compared with the beginning of treatment, most of these patients were still at least moderately depressed and unimproved. On the basis of the CGI-I, 10 (33.3%) were unchanged, 10 (33.3%) were minimally improved, 8 (26.7%) were very much or much improved, and 2 (6.6%) were worse. There was no evidence of an increase of irritability, mania, or sleep problems. A systematic search of the adverse event database for possible reports of symptoms suggestive of behavioral activation found that only in 1 case did the patient have insomnia, mood lability, and irritability in the 2 weeks prior to the suicidal event.

For 32 (72.7%) of the 44 patients with a suicidal event, an acute interpersonal conflict (youth-parent conflict in 27 [84.4%] and youth-peer conflict in 5 [15.6%] of the cases) was identified. In addition, 6 (13.6%) of the patients with a suicidal event had some identifiable recent legal problem. However, measures of family stressors or parent-child conflict at baseline were not significant predictors of suicidal events during TADS.

Disposition After Suicidal Events

Of the 44 patients experiencing a suicidal event, 24 (54.5%) were hospitalized for a period ranging from 1 to 9 days. Six others (13.6%) had only a hospital emergency room visit without inpatient hospitalization, while 14 (31.8%) had neither.

DISCUSSION

Previous publications have reported on the increased incidence of suicidal events observed in TADS among youths randomly assigned to fluoxetine monotherapy and the protective effect of CBT when combined with fluoxetine in decreasing suicidal risk.¹³⁻¹⁵ In this report, we present analyses of the timing of suicidal events and the possible associations between suicidal events and clinical characteristics at study entry or proximally to the event. The purpose was to identify possible predictors and immediate antecedents of suicidal behavior in depressed adolescents entering treatment without more specific risk factors for suicide. In fact, TADS participants were outpatients who were not abusing drugs or alcohol, had no psychotic or manic symptoms or history of recent suicide attempts or suicidal threats, and were not in acute crisis at study entry. One particular aim was to search for possible indicators of an antidepressant-induced behavioral activation syndrome preceding the suicidal event. If the increased rate of suicidal events observed while taking antidepressants was mediated by behavioral activation, one would expect suicidal events to occur in the initial period after starting medication and to be preceded by increases in irritability, mood instability, insomnia, and akathisia.

We found that time to suicidal event was variable, occurring as early as the first week and as late as 6 months after starting treatment, and that it was not shorter for patients treated with antidepressant medication than for those not taking medication. Overall, the rate of suicidal events was not higher in the first month of treatment than in the subsequent 2 months. Furthermore, there was no evidence of increased irritability, insomnia, or agitation in the 2 weeks prior to the event. Thus, these data do not support the hypothesis of medication-induced behavioral activation as a trigger for suicidal behavior during SSRI treatment. It must be observed, however, that TADS did not use a rapid dose escalation and that the starting dose was only 10 mg/d.

Although depressive symptoms had declined since entering treatment, most patients who became suicidal were still depressed at the time of the suicidal event, had not achieved a clinically adequate level of improvement, and reported some acute interpersonal stressor just before the event. These findings indicate that suicidal events during treatment occurred in a context of persistent depression, insufficient improvement, and an acute interpersonal conflict. In addition, the data indicate that suicidal events, even if not resulting in physical harm, often led to hospitalization and consequently had substantial cost implications.

The results also confirm the difficulty of predicting with any precision the emergence of suicidal behavior among clinically depressed patients. Even though pretreatment indexes of self-reported suicidal ideation (SIQ-Jr) and depressive symptomatology (RADS) were statistically associated with presenting with suicidal events during treatment, both the sensitivity and specificity of these instruments are suboptimal for diagnostic purposes, as also shown by ROC areas under the curve below 0.70 (accuracy is considered excellent if the area under the curve is 0.90-1.0, good if 0.80-0.90, fair if 0.70-0.80, and poor if 0.60–0.70). In any case, these data suggest that self-rated instruments of suicidality and depression are more sensitive in detecting suicidal risk than rating scales scored by the clinician (ie, CDRS-R). This finding is consistent with another study in adolescent depression.²⁷ Thus, youths appear more likely to indicate clinically relevant suicidal ideation when completing an assessment questionnaire themselves rather than to share these thoughts in a direct interview with a clinician.

Limitations

Several limitations must be acknowledged. Despite being one of the largest controlled clinical trials in adolescent depression, TADS is still rather small in sample size to allow adequate exploration of predictors and moderators of treatment. In fact, the power to detect predictors with a 2-tailed α of 0.05 was about 30% or less (according to the variable being tested). Because of this low power, we cannot rule out false-negative findings. Furthermore, the TADS was designed in 1999 and conducted before attention was brought to suicidality in antidepressant treatment in 2003 and subsequent years. The adverse event data were collected based on spontaneous patient report rather than systematically elicited by the investigators. This limitation is in part attenuated by the systematic administration of rating scales that included suicidal ideation and other relevant symptoms.

Another limitation is that the baseline assessment, although quite detailed, did not include a number of variables potentially relevant to suicidal behavior, such as family history of suicide. Finally, consistent with the TADS inclusion and exclusion criteria, the results of these analyses are limited to depressed youths who entered treatment while not being at high risk for suicide due to recent suicidal behavior, substance abuse, or stressful circumstances.

CONCLUSION

Depressed adolescents who manifest suicidal ideation at treatment entry are at increased risk for suicidal events during treatment. The risk for suicidal events does not seem to decrease after the first month of treatment, suggesting the need for maintaining close monitoring for several months after starting treatment. Most depressed adolescents presenting with suicidal events during treatment are still significantly depressed, with no or minimal signs of improvement, and without evidence of drug-associated behavioral activation.

Drug name: fluoxetine (Prozac and others).

Financial disclosure: Dr Silva has served as a consultant to Pfizer. Dr Kratochvil has received grant/research support from Eli Lilly, Somerset, Abbott, Shire, McNeil, and Cephalon; has served as a consultant to Eli Lilly, Pfizer, Cephalon, AstraZeneca, Organon, and Shire and on the speaker's board of Eli Lilly; and has received other financial or material support from National Institute of Mental Health (NIMH). Dr Posner has received funding from the US Food and Drug Administration (FDA) to develop and implement the suicidality classification system used in their safety analyses. As part of an effort to help execute the subsequent FDA suicidality classification mandates/recommendations, Dr Posner has had only research support from the following pharmaceutical companies: Eli Lilly, Pfizer, Valeant, Merck, Schering Plough, Orexigen, Forest, GlaxoSmithKline, and Sanofi-Aventis. Dr March has served as a consultant or scientific advisor to Pfizer, Eli Lilly, Wyeth, GlaxoSmithKline, and MedAvante; has received research support from Eli Lilly and Pfizer and currently receives support from NIMH; has received study drug for an NIMH-funded study from Eli Lilly and Pfizer; is an equity holder in MedAvante; and receives royalties from Guilford Press, Oxford University Press, and MultiHealth Systems. Drs Vitiello, Rohde, Kennard, and Reinecke and Mss Mayes and May report no financial affiliations relevant to the subject of this article.

REFERENCES

- American Psychiatric Association. *Diagnostic and Statistical Manual of* Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
- Bridge JA, Goldstein TR, Brent DA. Adolescent suicide and suicidal behavior. J Child Psychol Psychiatry. 2006;47:372–394.
- Foley DL, Goldston DB, Costello EJ, et al. Proximal psychiatric risk factors for suicidality in youth. *Arch Gen Psychiatry*. 2006;63: 1017–1024.

- Goldstein TR, Bridge JA, Brent DA. Sleep disturbance preceding completed suicide in adolescents. J Consult Clin Psychol. 2008;76:84–91.
- Gruenberg AM, Goldstein RD. Mood disorders: depression. In: Rasman A, Kay J, Lieberman JA, eds. *Psychiatry*. Vol. 2. 2nd ed. Chichester, United Kingdom: John Wiley & Sons; 2003:1207–1236.
- Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry*. 2006;63: 332–339.
- Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA*. 2007;297:1683–1696.
- Goodman WK, Murphy TK, Storch EA. Risk of adverse behavioral effects with pediatric use of antidepressants. *Psychopharmacology (Berl)*. 2007;191:87–96.
- Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behavior. JAMA. 2004;292:338–343.
- Simon GE, Savarino J, Operskalski B, et al. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163:41–47.
- Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. *Am J Psychiatry*. 2007;164:1029–1034.
- American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. *J Am Acad Child Adolesc Psychiatry*. 2007;46: 1503–1526.
- March J, Silva S, Petrycki S, TADS Team. Fluoxetine, cognitivebehavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. *JAMA*. 2004;292(7):807–820.
- March JS, Silva S, Petrycki S, TADS Team. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64:1132–1143.
- Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry. 2006;45(12):1440–1455.
- Treatment for Adolescents with Depression Study (TADS) Team. The Treatment for Adolescents with Depression Study (TADS): demographics and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2005;44:28–40.

- Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Maryland: National Institute of Mental Health;1976.
- Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicidal Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. *Am J Psychiatry*. 2007;164:1035–1043.
- Reynolds WM. Professional Manual for the Suicidal Ideation Questionnaire. Lutz, Florida: Psychological Assessment Resources, Inc;1987.
- Poznanski EO, Mokros HB. Manual for the Children's Depression Rating Scale-Revised. Los Angeles, California: Western Psychological Services; 1995.
- 21. Beck AT. *Beck Hopelessness Scale*. San Antonio, Texas: The Psychological Corporation; 1978.
- Reynolds WM. Professional Manual for Reynolds Adolescent Depression Scale. Odessa, Florida: The Psychological Assessment Resources, Inc; 1987.
- 23. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36(7):980–988.
- March JS, Parker JD, Sullivan K, et al. The Multidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. *J Am Acad Child Adolesc Psychiatry*. 1997;36:554–565.
- Skinner H, Steinhauer P, Sitarenios G. Family Assessment Measure (FAM) and Process Model of Family Functioning. *J Fam Ther.* 2000;22: 190–210.
- Robin AL, Foster SL. Negotiating Parent Adolescent Conflict: A Behavioral Family Support System Approach. New York, New York: Guilford; 1989.
- Bridge JA, Barbe RP, Birmaher B, et al. Emergent suicidality in a clinical psychotherapy trial for adolescent depression. *Am J Psychiatry*. 2005;162:2173–2175.

Editor's Note: We encourage authors to submit papers for consideration as a part of our Focus on Childhood and Adolescent Mental Health section. Please contact Karen D. Wagner, MD, PhD, at kwagner@psychiatrist.com.